An innovative pharmaceutical industry which meets the needs of society
Tuesday, 05 October 2010
European Medicines Agency and U.S. Food and Drug Administration extend confidentiality arrangements
Monday, 20 September 2010
New Report shows investment in malaria prevention paying off
Wednesday, 15 September 2010
Ukraine's antimonopoly committee fines pharma for illegal price hikes
Ukraine's antimonopoly committee (AMKU) has conducted 259 inspections of pharmaceutical manufacturers, wholesalers and retailers and initiated 101 legal investigations of competition law violations by the industry and regional healthcare authorities.
Source: www.scripnews.com 07.01.2010.
Turkmenistan faces "health crisis" unless TB treatment quickened, MSF warns
Planned programmes to tackle tuberculosis in Turkmenistan may not reach patients until 2013, despite high numbers of cases and growing transmission of multi-drug resistance, Médecins Sans Frontières (MSF) has warned.
Source: www.pharmexec.com 06.01.2010.
Zydus begins H1N1 trials
Zydus Cadila has become the first Indian pharma company to begin multi-centre clinical trials of a H1N1 vaccine after it received approval from the Drug Controller General of India (DCGI).
Source: in-Pharma tehnologist 05.01.2010.
Corrupt Practices Cost Healthcare $23 Billion
Fraud and abuse in healthcare costs individual governments as much as $23 billion a year, according to estimates from the World Health Organization (WHO).
The U.S. Food and Drug Administration (FDA)
The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.
Source: the medical news
The role of pharmacists hasn't received much attention in the debate on the cost of health care. But national and regional studies show that when pharmacists directly participate in patient care, they significantly reduce treatment costs and improve outcomes.
Uzbekistan is developing international collaborations in order to benefit from more advanced approaches to pharmaceutical production, after it signed agreements with at least two foreign companies in the second half of 2009.